Ronald S Veazey1. 1. Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana 70433, USA. rveazey@tulane.edu
Abstract
PURPOSE OF REVIEW: A number of microbicide candidates have failed to prevent HIV transmission in human clinical trials, and there is uncertainty as to how many additional trials can be supported by the field. Regardless, there are far too many microbicide candidates in development, and a logical and consistent method for screening and selecting candidates for human clinical trials is desperately needed. The unique host and cell specificity of HIV, however, provides challenges for microbicide safety and efficacy screening, that can only be addressed by rigorous testing in relevant laboratory animal models. RECENT FINDINGS: A number of laboratory animal model systems ranging from rodents to nonhuman primates, and single versus multiple dose challenges have recently been developed to test microbicide candidates. These models have shed light on both the safety and efficacy of candidate microbicides as well as the early mechanisms involved in transmission. This article summarizes the major advantages and disadvantages of the relevant animal models for microbicide safety and efficacy testing. SUMMARY: Currently, nonhuman primates are the only relevant and effective laboratory model for screening microbicide candidates. Given the consistent failures of prior strategies, it is now clear that rigorous safety and efficacy testing in nonhuman primates should be a prerequisite for advancing additional microbicide candidates to human clinical trials.
PURPOSE OF REVIEW: A number of microbicide candidates have failed to prevent HIV transmission in human clinical trials, and there is uncertainty as to how many additional trials can be supported by the field. Regardless, there are far too many microbicide candidates in development, and a logical and consistent method for screening and selecting candidates for human clinical trials is desperately needed. The unique host and cell specificity of HIV, however, provides challenges for microbicide safety and efficacy screening, that can only be addressed by rigorous testing in relevant laboratory animal models. RECENT FINDINGS: A number of laboratory animal model systems ranging from rodents to nonhuman primates, and single versus multiple dose challenges have recently been developed to test microbicide candidates. These models have shed light on both the safety and efficacy of candidate microbicides as well as the early mechanisms involved in transmission. This article summarizes the major advantages and disadvantages of the relevant animal models for microbicide safety and efficacy testing. SUMMARY: Currently, nonhuman primates are the only relevant and effective laboratory model for screening microbicide candidates. Given the consistent failures of prior strategies, it is now clear that rigorous safety and efficacy testing in nonhuman primates should be a prerequisite for advancing additional microbicide candidates to human clinical trials.
Authors: C Jane Batten; Robert De Rose; Kim M Wilson; Michael B Agy; Socheata Chea; Ivan Stratov; David C Montefiori; Stephen J Kent Journal: AIDS Res Hum Retroviruses Date: 2006-06 Impact factor: 2.205
Authors: Marion Ratterree; Agegnehu Gettie; Victoria Williams; Susan Malenbaum; A Robert Neurath; Cecilia Cheng-Mayer; James Blanchard Journal: AIDS Date: 2005-10-14 Impact factor: 4.177
Authors: C K Mauck; M M Callahan; J Baker; K Arbogast; R Veazey; R Stock; Z Pan; C S Morrison; M Chen-Mok; D F Archer; H L Gabelnick Journal: Contraception Date: 1999-07 Impact factor: 3.375
Authors: Ronald S Veazey; Martin S Springer; Preston A Marx; Jason Dufour; Per Johan Klasse; John P Moore Journal: Nat Med Date: 2005-11-06 Impact factor: 53.440
Authors: P A Marx; A I Spira; A Gettie; P J Dailey; R S Veazey; A A Lackner; C J Mahoney; C J Miller; L E Claypool; D D Ho; N J Alexander Journal: Nat Med Date: 1996-10 Impact factor: 53.440
Authors: Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Amir Horowitz; Arlene Hurley; Christine Hogan; Daniel Boden; Paul Racz; Martin Markowitz Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: Susan M Fetherston; Leslie Geer; Ronald S Veazey; Laurie Goldman; Diarmaid J Murphy; Thomas J Ketas; Per Johan Klasse; Sylvain Blois; Paolo La Colla; John P Moore; R Karl Malcolm Journal: J Antimicrob Chemother Date: 2012-10-28 Impact factor: 5.790
Authors: Mayla Hsu; Meropi Aravantinou; Radhika Menon; Samantha Seidor; Daniel Goldman; Jessica Kenney; Nina Derby; Agegnehu Gettie; James Blanchard; Michael Piatak; Jeffrey D Lifson; Jose A Fernández-Romero; Thomas M Zydowsky; Melissa Robbiani Journal: AIDS Res Hum Retroviruses Date: 2013-11-22 Impact factor: 2.205
Authors: S A Vishwanathan; A Burgener; S E Bosinger; G K Tharp; P C Guenthner; N B Patel; K Birse; D L Hanson; G R Westmacott; T R Henning; J Radzio; J G Garcia-Lerma; T B Ball; J M McNicholl; E N Kersh Journal: J Virol Date: 2015-06-24 Impact factor: 5.103
Authors: Todd J Johnson; Priya Srinivasan; Theodore H Albright; Karen Watson-Buckheit; Lorna Rabe; Amy Martin; Chou-Pong Pau; R Michael Hendry; Ron Otten; Janet McNicholl; Robert Buckheit; James Smith; Patrick F Kiser Journal: Antimicrob Agents Chemother Date: 2011-12-12 Impact factor: 5.191
Authors: Priya Srinivasan; Jining Zhang; Amy Martin; Kristin Kelley; Janet M McNicholl; Robert W Buckheit; James M Smith; Anthony S Ham Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: John A Moss; Amanda M Malone; Thomas J Smith; Irina Butkyavichene; Cassandra Cortez; Joshua Gilman; Sean Kennedy; Etana Kopin; Cali Nguyen; Preetha Sinha; R Michael Hendry; Patricia Guenthner; Angela Holder; Amy Martin; Janet McNicholl; James Mitchell; Chou-Pong Pau; Priya Srinivasan; James M Smith; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2012-09-10 Impact factor: 5.191